Business Results for the Third Quarter of the Fiscal Year Ending December 31, 2021 (Unaudited)

On November 10, 2021 Kuraray reported that (Press release, Kuraray, NOV 10, 2021, https://pdf.irpocket.com/C3405/l3Fa/TF2c/T3bA.pdf [SID1234595213])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2021 (January 1, 2020 to September 30, 2021)
(1) Consolidated Operating Results (Percentage changes displayed for net sales, operating income, ordinary income and net income attributable to owners of the parent are comparisons with the corresponding period of the previous fiscal year.)
(2) Consolidated Financial Position

2. Dividends
3. Forecasts of Consolidated Financial Results for the Fiscal Year Ending December 31, 2021 (January 1, 2021 to December 31, 2021) (Percentage changes displayed for net sales, operating income, ordinary income and net income attributable to owners of the parent are comparisons with the corresponding period of the previous fiscal year.)

1. Qualitative Information regarding Business Results
(1) Overview of Consolidated Business Results In the third quarter of fiscal 2021 (January 1, 2021–September 30, 2021), the world economy recovered overall as COVID-19 vaccinations rates continued to rise and economic activities have been invigorated, particularly in advanced countries and China. However, the outlook is currently growing more unclear due mainly to a continued rise in raw material and fuel prices in addition to shortages of semiconductors and other components, prolonged logistics disruptions, and concerns about an economic slowdown in China. Consequently, consolidated operating results for the third quarter of fiscal 2021 are as follows: net sales rose ¥65,380 million, or 16.6%, compared with the previous fiscal year to ¥459,159 million; operating income increased ¥21,790 million, or 67.0%, to ¥54,318 million; ordinary income increased ¥21,178 million, or 71.0%, to ¥51,001 million; and net income attributable to owners of the parent increased ¥13,455 million, or 88.8%, to ¥28,602 million.

The Group’s long-term vision for its 100th anniversary coming up in 2026, "Kuraray Vision 2026", is to become a "Specialty Chemical Company, growing sustainably by incorporating new foundational platforms into its own technologies." We will continue striving to optimize our business portfolio by steadily taking specific measures based on the three basic policies of "Kuraray Vision 2026": pursuing competitive superiority, expanding new business fields and enhancing the comprehensive strengths of the Kuraray Group. In fiscal 2021, we will focus on safe and stable operations amid the pandemic and thoroughly implement various measures decided on during the period of the previous medium-term management plan "PROUD 2020." At the same time, we will move ahead with formulating the next medium-term management plan, which is set to start in fiscal 2022.Results by Business Segment Vinyl Acetate Sales in this segment increased 20.4% year on year to ¥224,861 million, and segment income rose 53.3% year on year to ¥42,926 million.

(1) Sales of PVA resin increased for a wide range of applications as global demand has been recovering, but performance was impacted by high raw material and fuel prices. Sales of optical-use poval film were brisk against a backdrop of robust demand for LCD panels continuing from the second half of the previous fiscal year. The sales volume of PVB film rose year on year but were affected by a decrease in the production of automobiles caused by a shortage of semiconductors in the third quarter. Sales of water-soluble PVA film steadily expanded for use in unit dose detergent packets, including for laundry and dish detergents.
(2) The sales volume of EVAL ethylene vinyl alcohol copolymer (EVOH resin) increased due to a recovery in demand for gas tank applications and solid demand for food packaging applications but were affected by a decrease in the production of automobiles and high raw material and fuel prices in the third quarter.

Genocea to Present at the Stifel 2021 Virtual Healthcare Conference

On November 10, 2021 Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported that Chip Clark, president and chief executive officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17th at 1:20 PM ET (Press release, Genocea Biosciences, NOV 10, 2021, View Source [SID1234595190]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at View Source A replay of the webcast will be archived for 90 days following the presentation.

Acacia Pharma to Present at the Jefferies London Healthcare Conference on 16 November 2021

On November 10, 2021 Acacia Pharma Group plc ("Acacia Pharma", the "Group" or the "Company") (EURONEXT: ACPH), reported that its Chief Executive Officer, Mike Bolinder will present at the Jefferies London Healthcare Conference 2021 on Tuesday, 16 November 2021 (Press release, Acacia Pharma, NOV 10, 2021, View Source [SID1234595187]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will begin at 09:20 GMT / 10.20 CET and a live video webcast will be available to registered conference attendees. The link to the webcast is available here.

A replay will also be available to registered attendees for 30 days post the event via the same link.

The conference will also be attended by Acacia Pharma’s Chief Financial Officer, Gary Gemignani, and Chief Medical Officer, Gabriel Fox and alongside the presentation the Company will be conducting a series of 1×1 meetings with investors.

Presentation slides will be made available through the investor section of the Company’s website following the presentation.

Panbela Provides Business Update and Reports Q3 2021 Financial Results

On November 10, 2021 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, reported financial results for the quarter ended September 30, 2021 (Press release, Panbela Therapeutics, NOV 10, 2021, View Source [SID1234595186]). Management is hosting an earnings call today at 4:30 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The third quarter 2021 was marked by further meaningful clinical progress.

Recent Highlights

16 patients are in survival follow up since enrollment completed in December 2020, with 2 patients from cohort 2 now exceeding 26.9 and 28.7 months. Median overall survival for cohort 4 plus phase 1b (N=29) has not yet been reached.
Issue Notification for patent US 11,098,005 titled "METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL". A novel process for the production of our lead investigational product SBP-101, reduces the number of synthetic steps for its production from seventeen to six, and provides patent coverage to 2039.
$10.0 million bought offering of common stock closed July 2021.
"We have had a great third quarter and year to date," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer. "Highlights included reporting on 16 patients in survival follow up, since enrollment completed last December, with two patients north of 2-years. Additionally, we announced the issue notification to produce SBP-101. We also bolstered our balance sheet with the previously announced underwritten common stock offering, which will allow us to finish the current clinical trial, start a randomized trial in 2021 and expand into other cancer indications."

Upcoming Milestones

Initiation of randomized trial by year-end.
Initiation of a neoadjuvant study in pancreatic cancer by year-end.
Pre-clinical data which may support new development programs outside of pancreatic cancer by year-end and the initiation of a clinical trial in 1H ’22.
Third Quarter ended September 30, 2021 Financial Results

General and administrative expenses were $0.9 million in the third quarter of 2021, compared to $1.2 million in the third quarter of 2020. The decrease in the quarter is primarily associated with lower non-cash employee compensation.

Research and development expenses were $1.3 million in the third quarter of 2021, compared to $0.8 million in the third quarter of 2020. The increase in the quarter is due primarily to higher manufacturing costs in preparation for future clinical trials.

Net loss was $2.1 million, or $0.16 per diluted share, compared to a net loss of $1.7 million, or $0.21 per diluted share, in the third quarter of 2020.

Total cash and cash equivalents was $14.1 million as of September 30, 2021. Total current assets were $14.7 million and current liabilities were $1.3 million as of the same date.

The company had no debt as of September 30, 2021.

Conference Call Information

About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting potential complementary activity with an existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Serious visual adverse events have been evaluated and patients with a history of retinopathy or at risk of retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the current Panbela sponsored clinical trial provides support for continued evaluation of SBP-101 in a randomized clinical trial. For more information, please visit View Source .

Supernus to Participate in Upcoming November Investor Conferences

On November 10, 2021 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that the Company’s management will participate and host investor meetings at the following upcoming November 2021 investor conferences (Press release, Supernus, NOV 10, 2021, View Source [SID1234595185]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2021 Virtual Healthcare Conference
Date: November 15, 2021
Participation Type: Fireside Chat
Presentation Time: 2:00 p.m. EST

Jefferies London Healthcare Conference
Date: November 18, 2021
Participation Type: Fireside Chat
Presentation Time: Pre-recorded, available beginning November 18 at 3:00 a.m. EST / 8:00 a.m. GMT

A live webcast of the Stifel fireside chat, as well as replays of both fireside chats will be accessible by visiting Events & Presentations in the Investor section on the Company’s website at www.supernus.com. An archived replay of each webcast will be available for 60 days on the Company’s website after the respective conference.